Mark Johnson to Breast Neoplasms
This is a "connection" page, showing publications Mark Johnson has written about Breast Neoplasms.
Connection Strength
0.166
-
Loeian MS, Mehdi Aghaei S, Farhadi F, Rai V, Yang HW, Johnson MD, Aqil F, Mandadi M, Rai SN, Panchapakesan B. Liquid biopsy using the nanotube-CTC-chip: capture of invasive CTCs with high purity using preferential adherence in breast cancer patients. Lab Chip. 2019 06 07; 19(11):1899-1915.
Score: 0.086
-
Jamerson MH, Johnson MD, Korsmeyer SJ, Furth PA, Dickson RB. Bax regulates c-Myc-induced mammary tumour apoptosis but not proliferation in MMTV-c-myc transgenic mice. Br J Cancer. 2004 Oct 04; 91(7):1372-9.
Score: 0.031
-
Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest. 1993 Dec; 92(6):2569-76.
Score: 0.015
-
Kurebayashi J, McLeskey SW, Johnson MD, Lippman ME, Dickson RB, Kern FG. Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 and LacZ. Cancer Res. 1993 May 01; 53(9):2178-87.
Score: 0.014
-
Thompson EW, Br?nner N, Torri J, Johnson MD, Boulay V, Wright A, Lippman ME, Steeg PS, Clarke R. The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells. Clin Exp Metastasis. 1993 Jan; 11(1):15-26.
Score: 0.014
-
Jamerson MH, Johnson MD, Dickson RB. Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models. Oncogene. 2000 Feb 21; 19(8):1065-71.
Score: 0.006